David Rescott

Q: What is David Rescott's success rate?

David Rescott currently has a success rate of 95.58764718951345.

Q: What is the average return of David Rescott's calls?

Their stock ratings have generated an average return of 27.437758835011795.

Baird | Healthcare

David Rescott is an analyst from Baird specializing in the Healthcare sector. Ranked #701 out of 4773 analysts, they have issued 23 stock ratings with a success rate of 95.59% and an average return of 27.44%.

David Rescott has a well-established track record, with 23 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 95.59% and an average return of 27.44%, underscoring their expertise and ability to identify winning opportunities for investors.

#701

Out of 4773

Total Ratings

+95.59%

Success Rate

+27.44%

Average Return

Recent Ratings Analysis

HAE

Buy

Aug 21, 2026

Target

$119.00

Current

$106.31

Performance

-2.29%

David Rescott rated HAE as Outperform on Aug 21, 2026, setting a price target of 119. Shares have remained stable near 106.31, leaving the 119 target still in play.

HTFL

Buy

Jul 31, 2026

Target

$34.00

Current

$49.54

Performance

96.35%

On Jul 31, 2026, HTFL was given a Outperform rating by David Rescott, with a target price of 34. The stock rallied 96.35% after the rating, narrowing the gap to the target of 34 and validating the bullish stance.

ISRG

Buy

Jul 17, 2026

Target

$500.00

Current

$377.94

Performance

9.41%

ISRG received a Outperform rating from David Rescott on Jul 17, 2026, aiming for 500. Momentum has favored the Buy call, with shares climbing from 377.94 to 377.94, rewarding those who trusted the recommendation.

ABT

Buy

Jul 01, 2026

Target

$121.00

Current

$103.10

Performance

11.85%

On Jul 01, 2026, David Rescott published a Outperform outlook on ABT, with a target of 121. Shares gained 11.85%, underscoring the accuracy of the bullish outlook toward 121.

MDT

Hold

Jun 04, 2026

Target

$85.00

Current

$93.80

Performance

14.49%

David Rescott on Jun 04, 2026 assigned MDT a Neutral rating, with a price target of 85. Shares outperformed expectations, climbing 14.49% despite the neutral view.

BSX

Buy

May 19, 2026

Target

$75.00

Current

$45.05

Performance

-20.70%

On May 19, 2026, David Rescott reaffirmed BSX with a Outperform rating, targeting 75. Shares slid 20.70% despite the recommendation, highlighting downside risks.

LIVN

Buy

May 07, 2026

Target

$76.00

Current

$80.63

Performance

13.68%

LIVN was rated Outperform by David Rescott on May 07, 2026, with a price objective of 76. A bullish response from the market helped close the gap of -4.63 to the target.

EW

Hold

Apr 24, 2026

Target

$87.00

Current

$85.52

Performance

—

On Apr 24, 2026, David Rescott initiated coverage on EW with a Neutral rating and target of 87. The stock’s lack of movement around 85.52 aligned with a cautious approach.

PRCT

Hold

Mar 06, 2026

Target

$30.00

Current

$21.02

Performance

-13.21%

David Rescott issued a Neutral recommendation for PRCT on Mar 06, 2026, price target set at 30. Market action validated the conservative Hold outlook with shares at 21.02.

PEN

Hold

Jan 16, 2026

Target

$374.00

Current

$319.86

Performance

-8.81%

On Jan 16, 2026, PEN was evaluated by David Rescott, who gave a Neutral rating and target of 374. The Hold call avoided chasing into subsequent weakness of 8.81%.

SIBN

Buy

Dec 18, 2025

Target

$23.00

Current

$18.70

Performance

—

David Rescott rated SIBN as Buy on Dec 18, 2025, setting a price target of 23. Shares have remained stable near 18.7, leaving the 23 target still in play.

NARI

Hold

Jan 07, 2025

Target

$80.00

Current

$79.97

Performance

0.65%

On Jan 07, 2025, NARI was given a Neutral rating by David Rescott, with a target price of 80. Market indecision, reflected in sideways trading near 79.97, supported the cautious call.

IRTC

Buy

Jul 16, 2024

Target

$134.00

Current

$114.72

Performance

9.30%

IRTC received a Buy rating from David Rescott on Jul 16, 2024, aiming for 134. Momentum has favored the Buy call, with shares climbing from 114.72 to 114.72, rewarding those who trusted the recommendation.

MMSI

Buy

Jun 28, 2024

Target

$96.00

Current

$87.02

Performance

1.24%

On Jun 28, 2024, David Rescott published a Outperform outlook on MMSI, with a target of 96. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 87.02.

Frequency Asked Questions

Who is David Rescott?

David Rescott is an analyst from Baird specializing in the Healthcare sector.

What is David Rescott's success rate?

David Rescott currently has a success rate of +95.59%.

How many ratings has David Rescott issued?

David Rescott has issued 23 stock ratings so far.

What is the average return of David Rescott's calls?

Their stock ratings have generated an average return of +27.44%.

What is David Rescott's ranking?

David Rescott is ranked #701 out of 4773 analysts.

What types of ratings does David Rescott give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Rescott?

You can follow David Rescott by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Rescott?

Their latest rating was a Buy on HAE issued on 2026-08-21.